Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P40763 |
STAT3_HUMAN |
Psoriasis [ICD-11: EA90] |
P40763 |
STAT3_HUMAN |
Brain cancer [ICD-11: 2A00] |
P40763 |
STAT3_HUMAN |
Colorectal cancer [ICD-11: 2B91] |
P40763 |
STAT3_HUMAN |
Liver cancer [ICD-11: 2C12] |
P40763 |
STAT3_HUMAN |
Malignant digestive organ neoplasm [ICD-11: 2C11] |
P40763 |
STAT3_HUMAN |
Malignant haematopoietic neoplasm [ICD-11: 2B33] |
P40763 |
STAT3_HUMAN |
Pancreatic cancer [ICD-11: 2C10] |
P40763 |
STAT3_HUMAN |
Respiratory infection [ICD-11: CA07-CA4Z] |
P40763 |
STAT3_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P40763 |
STAT3_HUMAN |
Immune system disease [ICD-11: 4A01-4B41] |
P40763 |
STAT3_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P40763 |
STAT3_HUMAN |
Mature B-cell leukaemia [ICD-11: 2A82] |
P40763 |
STAT3_HUMAN |
Multiple myeloma [ICD-11: 2A83] |
P40763 |
STAT3_HUMAN |
Mycosis fungoides [ICD-11: 2B01] |
P40763 |
STAT3_HUMAN |
Ulcerative colitis [ICD-11: DD71] |
P40763 |
STAT3_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |